Sektor Protalix BioTherapeutics, Inc.

Aktien

A2PWSL

US74365A3095

PLX

Pharmazeutika

Markt geschlossen - 22:00:00 14.10.2026 Perf. 5 T Veränd. 1. Jan.
2.610 USD -5.09% Intraday Chart für Protalix BioTherapeutics, Inc. -3.69% +45.00%
Hauptkonkurrenten
% % 5 Tage Veränd. 1 Monat Veränd. 3 Monate % 1. Jan. Perf. 1 Jahr Perf. 3 Jahre Veränd. 5 Jahre Veränd. 10 Jahre Marktkap.($)
-5.09%-3.69%-5.78%+12.99%+45.00%+10.13%+76.35%+108.80%-48.63% 210 Mio.
+3.62%+1.68%+6.19%+4.88%+12.47%+48.80%+98.41%+410.68%+1’424.84% 1’077 Mrd.
+2.13%-1.76%-4.66%+0.02%+22.69%+33.04%+61.88%+58.58%+115.98% 612 Mrd.
+3.32%+4.47%+8.29%+15.81%+24.07%+23.72%+91.59%+160.29%+371.13% 501 Mrd.
+3.80%+3.21%+1.74%+22.02%+40.01%+73.99%+41.69%+88.14%+137.16% 364 Mrd.
+0.39%+5.70%+3.38%+12.90%+13.59%+31.22%+47.85%+3.48%+60.21% 353 Mrd.
+1.02%+5.47%+9.07%+1.77%+13.28%+19.34%+42.39%+61.39%+66.66% 278 Mrd.
+1.28%+5.03%+3.09%-0.60%-9.43%-1.22%+13.84%+42.01%+151.08% 251 Mrd.
+3.21%+3.15%+11.69%+19.95%+30.19%+45.01%+49.99%+106.07%+163.19% 230 Mrd.
+3.80%+4.56%+4.87%+18.07%+25.09%+29.59%+97.73%+125.30%+111.05% 190 Mrd.
+0.44%+3.04%-6.67%-22.10%-20.83%-29.24%-63.57%-21.73%+88.92% 168 Mrd.
+2.96%+4.32%+5.38%+20.45%+17.31%+19.13%-9.03%-29.90%-10.56% 166 Mrd.
+2.74%-1.41%-4.04%+4.66%+9.96%+20.93%+34.37%+174.05%+529.18% 126 Mrd.
+4.61%-0.70%-7.52%+4.09%+9.90%+35.34%+4.98%+2.74%+19.11% 121 Mrd.
+1.53%+7.28%+7.20%+21.56%+19.05%+24.90%+111.12%+380.93%+506.57% 114 Mrd.
+0.53%+1.82%-2.68%-5.30%-12.69%-14.31%-30.48%-13.86%+6.39% 95.7 Mrd.
+0.01%+5.07%-1.65%-4.85%-0.05%+12.01%+22.12%+4.23%-12.38% 95.69 Mrd.
+4.65%+15.18%+54.27%+235.56%+667.38%+762.10%+130.21%-31.81% - 90.35 Mrd.
+3.35%+4.88%-1.94%+18.63%+0.84%+35.93%-7.30%+40.09%+109.42% 77.72 Mrd.
+0.26%+4.97%+8.82%+1.68%+16.19%+22.33%-4.62%-25.94%+46.67% 68.62 Mrd.
Durchschnitt +1.45%+2.57%+4.45%+19.11%+46.20%+60.14%+40.48%+82.18%+201.89% 249.05 Mrd.
Nach Marktkapitalisierung gewichteter Durchschnitt +1.97%+1.91%+4.18%+11.89%+27.31%+45.10%+56.75%+145.03%+435.43%
  1. Börse
  2. Aktien
  3. A2PWSL Aktie
  4. Sektor Protalix BioTherapeutics, Inc.